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Abstract
Background: CD4
+CD25
+ regulatory T cell (Treg)-based immunotherapy is considered a promising regimen for controlling
the progression of autoimmune diabetes. In this study, we tested the hypothesis that the therapeutic effects of Tregs in
response to the antigenic epitope stimulation depend on the structural properties of the epitopes used.
Methodology/Principal Findings: Splenic lymphocytes from nonobese diabetic (NOD) mice were stimulated with different
glutamic acid decarboxylase (GAD)-derived epitopes for 7–10 days and the frequency and function of Tregs was analyzed.
We found that, although all expanded Tregs showed suppressive functions in vitro, only p524 (GAD524–538)-expanded
CD4
+CD25
+ T cells inhibited diabetes development in the co-transfer models, while p509 (GAD509–528)- or p530 (GAD530–
543)-expanded CD4
+CD25
+ T cells had no such effects. Using computer-guided molecular modeling and docking methods,
the differences in structural characteristics of these epitopes and the interaction mode (including binding energy and
identified domains in the epitopes) between the above-mentioned epitopes and MHC class II I-A
g7 were analyzed. The
theoretical results showed that the epitope p524, which induced protective Tregs, possessed negative surface-electrostatic
potential and bound two chains of MHC class II I-A
g7, while the epitopes p509 and p530 which had no such ability exhibited
positive surface-electrostatic potential and bound one chain of I-A
g7. Furthermore, p524 bound to I-A
g7 more stably than
p509 and p530. Of importance, we hypothesized and subsequently confirmed experimentally that the epitope (GAD570–
585, p570), which displayed similar characteristics to p524, was a protective epitope by showing that p570-expanded
CD4
+CD25
+ T cells suppressed the onset of diabetes in NOD mice.
Conclusions/Significance: These data suggest that molecular modeling-based structural analysis of epitopes may be an
instrumental tool for prediction of protective epitopes to expand functional Tregs.
Citation: Chen G, Han G, Feng J, Wang J, Wang R, et al. (2009) Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4
+CD25
+
Regulatory T Cells. PLoS ONE 4(9): e7034. doi:10.1371/journal.pone.0007034
Editor: Lisa F. P. Ng, Singapore Immunology Network, Singapore
Received February 11, 2009; Accepted August 11, 2009; Published September 13, 2009
Copyright:  2009 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Key Basic Research Program of China (2007CB512406) and the National Natural Science
Foundation of China (30801029). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: liyan62033@yahoo.com.cn
. These authors contributed equally to this work.
Introduction
Glutamic acid decarboxylase (GAD65), consisting of 585 amino
acids, has been shown to be the first of several b cell antigens to be
recognized by T cells from nonobese diabetic (NOD) mice and
patients with type 1 diabetes [1–3]. Its importance in the
pathogenesis of autoimmune diabetes is indicated by the following
evidence: 1. T cell responses against GAD65 can be detected in
youngNODmiceandinhumansatriskoftype 1diabetes[4,5];2.b
cell-specific suppression of GAD65 expression in antisense GAD65
transgenic NOD mice leads to complete prevention of type 1
diabetesand blocksthegeneration ofdiabetogenicT cells[6].These
findings suggest that modulation of GAD65 autoimmunity can
influence the development of type 1 diabetes in NOD mice.
It is known that GAD65 contains dozens of epitopes which are
specifically recognized by T cells as peptide epitope-MHC
complexes on the surface of target cells thereby directing T cell
function [7]. Indeed, pretreatment of prediabetic NOD mice with
GAD65 or some of its peptide epitopes efficiently delays the onset
of type 1 diabetes [8]. Strikingly, Quinn et al. [9] found the
presence of two kinds of epitopes (named as effector and regulatory
or protective epitopes) in GAD65 which were completely different
in their mediation of T cell function and the pathogenesis of
diabetes. Although many factors such as the mature state of
antigen processing cells (APC) contribute to determining whether
an epitope is an effector or regulatory epitope, the physical-
chemical properties of epitopes may have important effects on
their function. Differential structural properties of epitopes
probably lead to divergent conformation of MHC class II
molecules bound to the corresponding epitopes and ultimately to
differential T cell functional activation. Peptide epitope immuni-
zation in NOD mice is associated with the induction of Tregs that
secrete IL-10 and/or transforming growth factor (TGF)-b [10,11].
These cells have been shown to be pivotal for immune homeostasis
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that Tregs can be expanded by dendritic cells bearing an
autoantigenic peptide from pancreatic b cells [13]. Thus, we
postulate that there is a difference between effector and regulatory
epitopes in their ability to expand Tregs in vitro.
Previous research in our lab has demonstrated that a single
immunization of GAD500–585 (a peptide of GAD65) in young
NOD mice remarkably reduced pancreatic insulitis and efficiently
prevented the development of overt type 1 diabetes [14]. In fact,
GAD500–585 is composed of multiple epitopes such as 509–528,
524–538 and 530–543, which are important autoantigenic
peptides for the development of type 1 diabetes [1,9]. In this
study, the potential capacity of the above three peptide epitopes to
expand CD4
+CD25
+ T cells ex vivo was investigated and the in vivo
suppressive effects of these expanded CD4
+CD25
+ T cells were
then examined. Furthermore, a potential relationship between
the structure and function of these epitopes was analyzed by mole-
cular modeling/docking methods and a novel epitope p570 in
GAD500–585 which induced protective Tregs was presented.
Materials and Methods
Mice
NOD, and NOD.scid femalemice were obtained from the Jackson
Laboratory and bred in our facilities under specific pathogen-free
conditions. Care, use and treatment of mice in this study was in strict
agreement with guidelines in the care and use of laboratory animal
manual set out by the Institute of Basic Medical Sciences. Diabetes
monitoring was performed on a weekly measurement basis. The
female NOD mice develop overt diabetes at the age of 12 wks and
the incidence reaches 80% by 25 wks of age.
Epitope analysis and synthesis
The continuous epitopes of GAD500–585 were determined based
on its primary structure using the BIOSUN software [http://
www.biosun.org.cn/biosun/intro.htm, ref. 15] bearing in mind its
hydrophilic-hydrophobic properties [16], secondary structure [17],
antigenicity [18] and accessibility of the residues [19]. In order to
understand the relationship between sequence and structure in
greater depth, the 3-D structure of GAD500–585 was constructed
using the homology modeling method (InsightII software (2005),
Accelrys, San Diego, CA) based on the crystal structure of GAD65.
To optimize the packing interactions through protein side-chain
repacking, the 3-D modeled structure of GAD500–585 was
minimized with molecular mechanics method under Consistent
ValenceForce Field (CVFF) and Gromos96 force field, respectively.
Atomic charges were taken from the corresponding force field
package. Cross-terms were not used and energy convergence was
considered to have been obtained when the maximum derivative
reached 4.2 J/A ˚ by the conjugate gradients method.
The surface electrostatic potential was calculated based on the
stable 3-D structure of GAD500–585, using the DELPHI program
(InsightII software (2005), Accelrys, San Diego, CA). The charges
of the ionized groups were assigned assuming standard amino acid
protonation state at pH 7. Hisidines were considered in the
neutral form. The CVFF partial atomic charges were used and the
dielectric constant of GAD500–585 and solvent (i.e. water) were set
to 2 and 80, respectively. An ion exclusion layer was added to the
solutions and extended 10 A ˚ beyond the molecular surfaces. The
non-linear Poisson–Boltzmann equation was solved in the finite
difference approximation, and the numerical calculations of the
potential were iterated to convergence, which was defined as the
point at which the potential changes less than 10
24 kT/emol
between successive iterations.
GAD peptides p509, p524, p530 and p570 were synthesized at
Genemed Synthesis, and were brought to .90% purity using
reverse phase HPLC. Peptide purity was determined by capillary
electrophoresis, and the amino acid composition of the peptides
was verified by mass spectrometry. Ovalbumin (OVA) was
purchased from Sigma-Aldrich (USA).
Molecular docking
3-D structures of the above-mentioned peptides were construct-
ed using the ab initio modeling method [20,21]. Firstly, secondary
structures of the peptides were predicted and dihedral angles were
determined. 3-D original structures of the peptides were then
modeled. Finally, the stable structures of the peptides were
obtained under CVFF using molecular mechanics optimization.
Using the 3-D crystal structure of the MHC II molecule and the
modeling structure of the GAD65 peptide in complex with murine
MHC class II I-A
g7 (PDB code: 1es0) as templates, bearing in
mind Van der Waals and intermolecular hydrogen bonding
interactions, the 3-D structures of the peptides in complex with the
MHC class II molecule were constructed and optimized with the
molecular docking method.
In order to minimize steric clashes and ensure correct
interaction non-bond distances, angles and hydrogen bonds after
molecular docking, the interaction domains between the peptides
and MHC class II molecule were subjected to 5000 steps of energy
minimization, while the remainder was held fixed in position. To
avoid the conformation of the interaction domains trapped in a
local potential energy minimum, residues at the base of the
interaction domains were held fixed while the remainder of the
interaction domains was subjected to simulated heating and
molecular dynamics at elevated temperatures followed by slow
cooling to a low energy conformation. The interaction domain
residues were initially assigned a temperature of 300K and slowly
heated to 500K in increments of 25K, with 50 dynamics steps at
each temperature using a time step of 1 fs. The structure was
similarly heated to 1000, 2000, 3000 and 4000K. At each
temperature the interaction domains were subjected to a 100 ps
dynamics run followed by slowing to 300K, and two series of
minimizations, first for 500 steps, then 3000 steps.
Flow cytometry
Antibodies used for flow cytometry were as follows: PE-labeled
mAbs to CD4 (GK1.5), LAG-3 (C9B7W), CTLA-4 (UC10-4F10-
11) and ICOS (7E.17G9) were purchased from BD Pharmingen,
and FITC-labeled anti-CD4 (GK1.5) and PE-Cy5-labeled anti-
CD25 (PC61) mAbs, PE-conjugated mAbs against GITR (DTA-1),
and Foxp3 (FJK-16s) were purchased from eBioscience. Cells were
stained in PBS containing 2% heat-inactivated FCS and 0.2%
sodium azide, and fixed using PBS containing 1% paraformalde-
hyde. For intracellular staining, cells were first stained with Abs for
30 min and then fixed for 20 min with 1 ml fixation buffer (Fix &
Permcell permeabilization kit; eBioscience). After washing,thefixed
cells were incubated with Abs for 30 min. Data collection and
analysis were performed on a FACS Calibur flow cytometer using
CellQuest software (Becton Dickinson).
In vitro expansion of epitope-specific T cells
Splenic lymphocytes were isolated from 4–8 wk old female
NOD mice and cultured with different peptide epitopes or OVA
control (50 ng/ml) in RPMI-1640 medium, which consisted of 1%
horse serum (Hyclone), nonessential amino acids, 0.5 mM sodium
pyruvate, 5 mM Hepes, 1 mM b-mercaptoethanol. The cultures
were monitored daily and maintained at 121.5610
6/ml by
diluting with complete medium for 7–10 days.
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+CD25
+ T cells and in vitro suppression
assays
Purification of CD4
+CD25
+ T cells by MACS (Miltenyi Biotec,
Germany) was as described previously [22]. In brief, CD4
+ T cells
were isolated by depletion of magnetically labeled non-CD4
+ T
cells. CD4
+ T cells labeled with PE-conjugated anti-CD25 were
then magnetically labeled with anti-PE microbeads. The magnet-
ically labeled cells were passed through a column placed in the
magnetic field of a MACS separator and separated into
CD4
+CD25
+ and CD4
+CD25
2 T cells (purity.96%).
For suppression assays, graded numbers of expanded or freshly
purified CD4
+CD25
+ T cells were added to 50,000 CD4
+ T cells
stimulated with 50,000 irradiated splenic APCs (2,000 rads) and
1 mg/ml anti-CD3 in U-bottomed 96-well plates. CD4
+ T cell
cultures without CD4
+CD25
+ T cells were stimulated in the same
manner as positive controls. The cultures were maintained at 37uC
for a total of 72 h and cell proliferation was measured by
incorporation of [
3H]thymidine (1 mCi/well) during the final 16 h
of culture.
Adoptive transfer
Epitope-expanded CD4
+CD25
+ T cells were purified as
described above and injected intravenously (at different cell
numbers, as indicated) into 4–8 wk old NOD.scid mice along
with diabetogenic splenocytes isolated from acutely diabetic NOD
mice. Recipients only receiving diabetogenic splenocytes were
regarded as positive controls. In some experiments, expanded
CD4
+CD25
+ T cells (123610
6) were transfused into 4–6 wk old
NOD mice. In combination of adoptive transfer, some mice
received intraperitoneally antibodies to IL-10/TGF-b or isotype
IgG (all from R&D systems), respectively. The regimens of
antibodies to IL-10 and TGF-b administration were following: a
dose of 0.5 mg/mouse on days 21, 0, 2, 5, then every 5 days for
anti-IL-10; a dose of 1 mg/mouse on days 0, 3, 5, 8, then every 5
days for anti-TGF-b. Nonfasting blood glucose levels in recipient
mice were monitored using a MediSense glucometer (Abbott
Laboratories) and blood glucose $300 mg/dl was considered
diabetic.
ELISA of cytokine production
After splenocytes were incubated as described above, superna-
tants were harvested and IL-2, IL-10 and TGF-b production was
assayed by sandwich ELISA. The ELISA kits used in this study
were purchased from BD Pharmingen.
Statistical analysis
The Kaplan-Meier method was used to compare diabetes-free
survival and incidence. The Student’s t-test was used to compare
mean values. Values of P,0.05 were considered significant.
Results
GAD500–585-derived peptide epitope stimulation expands
CD4
+CD25
+Foxp3
+ T cells from NOD mice
Steinman and colleagues reported that b-cell autoantigenic
peptide-bearing dendritic cells (DCs) expanded functionally
competent Tregs which subsequently suppressed diabetes devel-
opment in an antigen-specific manner [13]. Here, in order to
determine whether known autoantigenic epitopes of GAD500-585,
such as p509, p524 and p530, could also expand suppressive
Tregs, splenic lymphocytes from autoimmune diabetes-prone
NOD mice were exposed to stimulation from different peptide
epitopes for 7–10 days. Since Foxp3 is known to be a master
regulator for CD4
+CD25
+ Treg development [23–25],
CD4
+CD25
+Foxp3
+ T cells were examined. We found that the
percentage and number of these cells increased 2–10 fold in
response to stimulation with the above peptide epitopes compared
to controls (Figure 1a and 1b). In addition, Treg-associated
molecules, such as cytotoxic T lymphocyte-associated antigen
(CTLA)-4 [26], glucocorticoid-induced TNFR-related protein
(GITR) [27], inducible costimulator (ICOS) [28] and lymphocyte
activation gene (LAG)-3 [29], were also up-regulated compared to
controls (Figure 1c).
To further determine whether the peptide epitope-expanded
CD4
+CD25
+ T cells were functionally suppressive, these expanded
cells were examined for their ability to suppress CD4
+ T effector
cells (Teffs) from diabetic NOD mice. Tregs and Teffs were co-
cultured in the presence of anti-CD3 and irradiated APC at a
titred ratio. Results showed that the expanded CD4
+CD25
+ T
cells efficiently suppressed proliferation of effector cells. This
suppressive effect was more potent than for freshly isolated Tregs,
as suppression was routinely observed at a Treg/Teff ratio
of ,1:32 (Figure 2). These results show that suppressive
GAD500–585 epitope-expanded CD4
+CD25
+ Tc e l l sc a nb eo b t a i n e d
in vitro by addition of peptide epitopes to pulse splenic APC.
Next, to determine the mechanisms underlying inhibitory effects
of the expanded CD4
+CD25
+ T cells, we examined their cytokine
profiles in response to differential epitope stimulation. The
CD4
+CD25
+ T cells from each group secreted high amounts of
IL-2 (Figure 3a), in line with the hypothesis that IL-2 is a key
cytokine for expansion and survival of Tregs [30,31]. Strikingly,
CD4
+CD25
+ T cells produced more IL-10 and TGF-b in response
to p524 stimulation than in response to p509 or p530 stimulation
(Figure 3b and 3c), indicating that p524-expanded CD4
+CD25
+
T cells may be more competent. We also examined IL-4 and IFN-
c production, but no significant differences were found between
the p509, p524 and p530 stimulation groups (data not shown).
In vitro-expanded CD4
+CD25
+ T cells suppress adoptive
transfer of diabetes in vivo
Using a co-transfer model, we subsequently examined the ability
of epitope-expanded CD4
+CD25
+ T cells to suppress diabetes
when co-transferred with diabetogenic T cells (1610
7 cells/mouse)
into NOD.scid mice. Interestingly, we found that p524-expanded
CD4
+CD25
+ T cells (3610
6) effectively blocked diabetes transfer,
whereas the other two types of epitope-expanded CD4
+CD25
+ T
cells did not show such protective effects, even when much higher
numbers of expanded CD4
+CD25
+ T cells were used (Figure 4).
Furthermore, neutralizing antibodies to IL-10/TGF-b were
administrated to evaluate the role of IL-10/TGF-b in p524-
expanded CD4
+CD25
+ T cell-mediated prevention from diabetes
transfer. The results showed that blockade of IL-10/TGF-b
bioactivities in vivo dramatically abrogated the suppressive effects
of p524-expanded CD4
+CD25
+ T cells on adoptively transfer of
diabetes (Figure 4b). Intriguingly, the neutralization of one of
these two cytokines (IL-10 or TGF-b) just had minor effects on
Treg-mediated blockade of diabetes development (data not
shown), indicating a complementary role of IL-10 or TGF-b in
mediating Treg protective effects when one cytokine was removed.
We also examined the ability of polyclonal CD4
+CD25
+ T cells
expanded by anti-CD3 plus IL-2 for inhibition of diabetes transfer.
Consistent with a previous report [32], our results showed that
high numbers of these CD4
+CD25
+ T cells (6610
6) were
insufficient to prevent diabetes (data not shown).
In vitro-expanded CD4
+CD25
+ T cells delay or suppress
the onset of diabetes in prediabetic NOD mice
Since the immunoregulatory activity of Tregs based on adoptive
transfer models that take advantage of lymphopenic settings to
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+CD25
+ Foxp3
+ T cells by peptide epitope stimulation. Splenic lymphocytes were isolated from one
NOD mice (total number of mice was 6) and cultured with different peptide epitopes (50 ng/ml) for 7-10 d. Cells were collected and analysed by flow
cytometry. (a) The percentages of CD25
+Foxp3
+ within CD4
+cells were presented. (b) Total number of CD4
+CD25
+Foxp3
+ T cells in each group after
expansion. Data collected from three independent experiments are shown. (c) Expression of Treg-related phenotypes (CTLA-4, GITR, ICOS, LAG-3) in
CD4 T cells from each group. As controls, OVA (50 ng/ml) stimulation could not expand CD4
+CD25
+Foxp3
+ T cells and up-regulate the expression of
Treg-related molecules (data not shown). Data are shown as means6SD, n=5–6 per group. *, P,0.05 compared with controls.
doi:10.1371/journal.pone.0007034.g001
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or a side effect of competition for ‘‘space’’ [33,34], we further
investigated the diabetes-suppressive function of Tregs in a
nonlymphopenic autoimmune diabetes-prone NOD mouse mod-
el. Previous studies have shown that NOD mice are deficient in
Treg number and function [35–37] and that intravenous transfer
of b cell-specific ex vivo expanded Tregs into NOD mice actively
prevents diabetes [38,39]. Thus, 4–6 wk old NOD mice were
injected with 123610
6 CD4
+CD25
+ T cells and subsequently
monitored for diabetes. Transfer of as few as 1610
6 p524-
Figure 2. In vitro suppression by expanded CD4
+CD25
+ T cells. CD4
+CD25
+ T cells (R) with or without peptide epitope stimulation were
compared for their ability to suppress the proliferation of CD4
+ effector T cells (E) stimulated with anti-CD3 and irradiated APC at graded ratios. The
proliferation was measured by [
3H]thymidine uptake. Results are shown as means6SD. The data were collected from six to eight separate
experiments.
doi:10.1371/journal.pone.0007034.g002
Figure 3. Cytokine production of expanded CD4
+CD25
+ T cells after peptide epitope stimulation. After 7–10d incubation with different
peptide epitopes, the IL-2, IL-10 and TGF-b production of expanded CD4
+CD25
+ T cells was determined by sandwich ELISA. Results are shown as
means6SD. The data were collected from four to six separate experiments. *, P,0.05 compared with controls.
doi:10.1371/journal.pone.0007034.g003
Modeling and Epitope Analysis
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+CD25
+ T cells per mouse markedly prevented/
delayed the development of diabetes for as long as 25 wk after
transfer (Figure 5a), whereas transfer of similar or even 3-fold
greater numbers of p509 or p530-expanded CD4
+CD25
+ T cells
only had a slight preventive effect on diabetes incidence
(Figure 5a and 5b). In this setting, we also examined whether
IL-10/TGF-b cytokines played an essential role in p524-expanded
CD4
+CD25
+ T cell-mediated delayed development of diabetes.
The findings showed that neutralization of IL-10/TGF-b in vivo
significantly abolished the protective effects of these cells
(Figure 5b), indicating that the immunoregulatory function of
p524-expanded CD4
+CD25
+ T cells was partially attributed to
high amounts of IL-10/TGF-b produced by these cells. Taken
together, these results suggested that Treg-mediated inhibition of
diabetes development is epitope-specific.
GAD500–585 epitope structure-function study
To determine whether this distinction in the Treg-expanding
function of these epitopes was related to differences in their
structural properties, physical and chemical features of p509, p524
and p530 were studied by surface property analysis and molecular
modeling methods. The continuous epitopes of the GAD500–585
sequence were analyzed using BIOSUN software. As shown in
Figure 6, peaks of the analyzed curve denoted the center of the
continuous epitopes and peptides 509–528, 532–545, 530–543,
550–556, 562–574, and 570–584 appear to be the main epitopes of
GAD500–585. In the above experiments, the epitopes p509 and p530
could be identified clearly, however p524 (GAD524–538) appeared
toinclude twopotentialepitopes(i.e.theC-terminal ofp509 andthe
N-terminal of p532). The predicted epitopes p509 and p530 were
composed of one core epitope, while the epitope p524 was made up
of two core epitopes. Our results are in line with a recent report that
p524 and p530 share one core and that flanking residues are critical
for their function [40]. Taken together, these results show a
potential difference between p524, and p509 as well as p530.
To understand more deeply the structure-function relationship
of the epitopes, the 3-D structure of GAD500–585 was modeled and
optimized based on the crystal structure of GAD from the PDB
database (PDB code: 2okk) and the predicted secondary structure
of GAD500–585 (data not shown), as shown in Figure 7a. It can be
seen that GAD500–585 is composed of three alpha helices and three
beta sheets. Due to the presence of five proline residues, the 3-D
structure of GAD500–585 is compact. Our computer-modeled 3-D
structure of GAD500–585 was very similar to that in the original
protein structure of GAD, and the RMSD (Root Mean Square
Distance) value of main chain carbon atoms between GAD500–585
and GAD was 0.0464 nm.
Furthermore, according to the modeling 3-D structure of
GAD500–585, the surface electrostatic potential distribution of
GAD500–585 was analyzed using DELPHI program. The calculat-
ed values are shown in Figure 7b. Results showed that fragments
p509 and p530 possessed positive surface electrostatic potential,
Figure 4. P524-expanded CD4
+CD25
+ T cells prevented transfer of diabetes. Diabetic splenocytes (1610
7) were co-transferred with or
without CD4
+CD25
+ T cells expanded by p509 (a), p524 (b), or p530 (c), to 4–8 wk old NOD.scid mice at the numbers indicated. In some cases,
NOD.scid recipients receiving 6610
6 p524-expanded CD4
+CD25
+ T cells were injected with neutralizing antibodies to IL-10/TGF-b according to the
regimens described in Materials and Methods. Blood glucose was monitored for up to 8 wks. Differences in blood glucose levels between diabetic
spleens alone and diabetic spleens plus 3610
6 p524-expanded CD4
+CD25
+ T cells were significant (P=0.003), as were differences between diabetic
spleens alone and diabetic spleens plus 6610
6 p524-expanded CD4
+CD25
+ T cells (P=0.002). Cumulative data from three experiments are shown.
The number of mice in each group is indicated in parentheses.
doi:10.1371/journal.pone.0007034.g004
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electrostatic potential. The surface electrostatic potential difference
of the peptides might be related to their bio-function. The peptides
p509 and p530 might possess the similar function while p524 and
p570 had the similar abilities.
In summary, together with the experimental results, the
conclusion is made that differences in the functions of p524,
p509 and p530 in expanding competent Tregs may be due to
differences in their structural properties.
The structural mode of interaction with MHC II varies
with peptide epitope
The 3-D structures of the peptide epitopes p509, p524, p530
and p570 were modeled using secondary structure prediction and
ab initio modeling methods, and 3-D structures of the interaction of
peptide epitopes with I-A
g7 were constructed by molecular docking
methods, according to the 3-D crystal structure of MHC II I-A
g7
in complex with p207 (PDB code: 1es0). Optimized 3-D structures
are shown in Figure 8. The peptide p286 from GAD65 (286–
300), whose transgenic expression delayed the onset of diabetes
[41], was also analyzed by way of comparison. Results showed that
p524 and p570 possessed a similar binding pattern to that of I-A
g7
with p286. The two peptides interacted with the middle of the I-
A
g7 chain A and B. In contrast, peptides p509 and p530 interacted
with I-A
g7 chain B, but not with chain A.
Interaction energies of p286, p509, p524, p530 and p570 in
complex with I-A
g7 were calculated based on 3-D modeling
structures. As shown in Table 1, the energy of p524 binding to I-
A
g7 was markedly lower than that of p509 and p530, but comparable
to that of p286 and p570. To understand the mode of interaction
between the peptides and I-A
g7more fully, the domains in the peptide
sequence were identified by computer graphics technology and
distance geometry methods and were shown in Table 2.
Overall, considering differences in structures of the peptide-
MHC class II complexes, interaction energies and identified
domains, we concluded that peptides p524 and p570 possessed
similar structures to p286, while peptides p509 and p530 were
significantly different from the above peptides. Thus, we
hypothesized that p570 might be a protective epitope.
P570 stimulation expands CD4
+CD25
+Foxp3
+ T cells from
NOD mice
To test this hypothesis, the ability of p570 to expand
CD4
+CD25
+ T cells was examined. Results showed that the
stimulation of p570 led to a significant increase in the frequency
and number of CD4
+CD25
+Foxp3
+ T cells after 7–10 days culture
(Figure 9a and 9b). Treg-associated phenotype expression,
including CTLA-4, GITR, ICOS, and LAG-3, was also markedly
up-regulated (Figure 9c). The suppressive capacity of these
expanded CD4
+CD25
+ T cells was determined by active
inhibition of the proliferation of Teffs (Figure 9d). CD4
+CD25
+
T cells expanded by p570 stimulation produced high levels of IL-2,
IL-10 and TGF-b comparable to those induced by p524
stimulation (Figure 9e). Taken together, these data indicate that
p570 was a potential epitope for Treg expansion.
P570-expanded CD4
+CD25
+ T cells suppress diabetes devel-
opment in cotransfer models
We also investigated the suppressive function of p570-expanded
CD4
+CD25
+ T cells in two transfer models as described above.
Like p524-expanded CD4
+CD25
+ T cells, p570-expanded
CD4
+CD25
+ T cells actively inhibited diabetes transfer to
NOD.scid mice (Figure 10a), and the transfer of 1610
6 p570-
stimulated CD4
+CD25
+ T cells was sufficient to prevent overt
autoimmunity in young NOD mice (Figure 10b). Again, our data
indicated that p570-expanded CD4
+CD25
+ T cell-mediated
protective effects in two models were partially due to IL-10/
TGF-b secretion of these cells as blockade of IL-10/TGF-b
activities in vivo dramatically abrogated the prevention from
diabetes development which was mediated by p570-expanded
CD4
+CD25
+ T cells (Figure 10a and b). Overall, these data
suggest that p570 is also a protective peptide epitope.
Discussion
Cell therapy for treating progressive autoimmune diseases based
on in vitro expansion of Tregs has been established in the past few
years [39,42–43]. However, the efficiency of this strategy requires
further improvement. Key issues needing to be resolved is whether
the acquisition of therapeutic Tregs depends on the peptide
epitope used and dissecting the relationship between the physical-
chemical properties of epitopes and their function in inducing/
expanding therapeutic Tregs. In the current study, we first
addressed the capacity of three epitopes from the GAD500–585
Figure 5. P524-expanded CD4
+CD25
+ T cells prevented/de-
layed the onset of diabetes in autoimmune diabetes-prone
NOD mice. 4–6 wk old NOD mice were transfused with CD4
+CD25
+ T
cells (either 1610
6 (a) or 3610
6 (b) per mouse) expanded by p509, p524
or p530. Untreated littermates were used as controls. In some cases,
NOD recipients receiving 3610
6 p524-expanded CD4
+CD25
+ T cells
were injected with neutralizing antibodies to IL-10/TGF-b according to
the regimens described in Materials and Methods. Development of
diabetes was monitored for over 25 wks and the cumulative incidence
of diabetes was shown from two experiments. The difference between
untreated controls and mice treated with 1610
6 p524-expanded
CD4
+CD25
+ T cells was significant (P=0.0036), as was that between
untreated controls and mice treated with 3610
6 p524-expanded
CD4
+CD25
+ T cells (P=0.0015). The number of mice in each group is
indicated in parentheses.
doi:10.1371/journal.pone.0007034.g005
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expand CD4
+CD25
+Foxp3
+ T cells in vitro. CD4
+CD25
+ T cells,
expanded in response to stimulation with either epitopes p509,
p530 or p524, exhibited excellent suppressive capacity in vitro.
Intriguingly, when their suppression capability was tested in vivo,
only p524-pulsed CD4
+CD25
+ T cells exhibited suppressive effects
on diabetes development in co-transfer models.
This discrepancy between in vivo and ex vivo data appears not to
result from the transfer of fewer p509 or p530-expanded
CD4
+CD25
+ T cells compared to those expanded by p524, as
even a 3–5 fold increase (e.g. 325610
6) in p509 or p530-
expanded CD4
+CD25
+ T cells failed to inhibit transfer of diabetes
(Figure 4). The data presented in this study indicate that this
failure to inhibit transfer of diabetes may be attributed to the
Figure 6. Epitopes in GAD500–585 were predicted using BIOSUN software bearing in mind sequence properties, the hydrophobic-
hydrophilic map, secondary structure, antigenicity and accessibility. The X-coordinate denoted the sequence location in GAD500–585, of
which the first value was the NO. 500 residue in GAD65 and the rest was deduced by analogy. The Y-coordinate denoted the statistical value from the
sequence properties (including the hydrophobic-hydrophilic map, secondary structure, antigenicity and accessibility). The curve peak indicated the
most possible key residue to form epitope. The region up the red line denoted the possible epitopes, and the region down the blue line denoted the
impossible epitopes. The region between the blue and red lines indicated uncertain/potential epitopes. The peptides used in our study are marked as
p509, p524, p530 and p570. The beginning and end points of the peptides are marked as vertical lines.
doi:10.1371/journal.pone.0007034.g006
Figure 7. 3-D structure and surface properties of GAD500–585. (a) 3-D modeling structure of GAD500–585, derived from the crystal structure of
GAD65 using a computer modeling homology method and optimized using molecular mechanism and molecular dynamics methods under a CVFF
forcefield, was shown as ribbon map and the secondary structure (composed of beta sheets and turns) was analyzed. (b) Surface electrostatic
potential of the peptides p509, p524, p530, p570. The surface electrostatic potential of the residues in GAD500–585 was calculated using the DELPHI
program, and the total surface electrostatic potential distribution of the peptides was summed. The positive value in Y-coordinate denoted the
peptides possessed the positive surface electrostatic potential, and vice versa.
doi:10.1371/journal.pone.0007034.g007
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+CD25
+ T cells.
P524-expanded CD4
+CD25
+ T cells produced higher levels of IL-
10 and TGF-b than those expanded by p509 or p530 stimulation.
Furthermore, in vivo neutralization of IL-10/TGF-b bioactivities
led to the abrogation of protective effects of p524-expanded
CD4
+CD25
+ T cells (Figure 4b and 5b), which is consistent with
the well-accepted conception that these two categories of cytokines
are recognized as important mediators of Treg immunomodula-
tory function [44,45]. In addition, differences between epitope-
expanded CD4
+CD25
+ T cells in terms of migration to or re-
activation in the draining lymph nodes also need consideration.
Tang et al. [32] proposed that ex vivo-expanded BDC2.5-specific
Tregs underwent significant proliferation after transfer into NOD
mice. However, expanded GAD286-specific Tregs failed to
proliferate in pancreatic lymph nodes. Whether this difference in
proliferation and/or migration in vivo is also present in p524, p509
or p530-expanded CD4
+CD25
+ T cells when transfused into
NOD mice needs to be elucidated in further studies.
As well known, to deeply understand the biological role of the
protein or peptides, the 3-D structure of them will be required.
Although experimental structure determination methods are
providing high-resolution structure information about a subset of
Figure 8. 3-D optimized structures of the peptides (p286, p509, p524, p530 and p570) in complex with MHC class II I-A
g7 using
molecular docking and molecular dynamics methods. The red ribbon denoted the peptides and the blue and green ribbons denoted the
dimer of the MHC class II I-A
g7. The peptides p509 and p530 bound monomer of the MHC class II I-A
g7, while the peptides p524 and p570 bound the
core domain of the dimmer similar to the peptide p286.
doi:10.1371/journal.pone.0007034.g008
Table 1. The interaction energy (KJ/mol) between the
indicated peptides and I-A
g7.
The complex of the
peptides and I-A
g7 The interaction energy (KJ/mol)
Van Der Waals Electrostatic Total energy
p286-I-A
g7 275.45 275.74 2151.19
p509-I-A
g7 236.37 243.97 280.34
p524-I-A
g7 284.94 278.63 2163.57
p530-I-A
g7 231.43 237.62 269.05
p570-I-A
g7 269.10 2107.13 2176.23
Interaction energies were calculated under CVFF based on the 3-D theoretical
structure of the peptides in complex with MHC class II I-A
g7. The theoretical
interaction energy was composed of Van der Waals interactions and
electrostatic potential.
doi:10.1371/journal.pone.0007034.t001
Table 2. The identified domain in I-A
g7 by the indicated
peptides.
The complex of the
peptides and I-A
g7
The identified
domains in I-A
g7
p286-I-A
g7 A55, A57, A61, A67, B60, B64, B66, B70
p509-I-A
g7 B76, B77, B81, B83
p524-I-A
g7 A55, A57, A61, B69, B70, B73
p530-I-A
g7 B21, B22, B76, B81, B83
p570-I-A
g7 A53, A55, A57, A61, B64, B69, B70, B73
Interaction domains were determined using computer graphic technology and
distance geometry methods based on the 3-D structures of the peptides in
complex with MHC class II I-A
g7.
doi:10.1371/journal.pone.0007034.t002
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+CD25
+ T cells by p570 stimulation. Splenic lymphocytes were isolated from one NOD mice (total number
of mice is 8) and cultured with synthesized p570 (50 ng/ml) for 7–10 d. Cells were collected and assayed by flow cytometry. (a) The percentage of
CD25
+Foxp3
+ within CD4
+cells was presented. (b) Total number of CD4
+CD25
+Foxp3
+ T cells in each group after expansion. Data collected from three
independent experiments are shown. (c) Expression of the Treg-related phenotype (CTLA-4, GITR, ICOS, LAG-3) in CD4 T cells in each group. (d) Fresh
and p570-expanded CD4
+CD25
+ T cells (R) were compared for their ability to suppress proliferation of CD4
+ effector T cells (E) under the same
conditions as other peptides indicated above. (e) After incubation with p570, IL-2, IL-10 and TGF-b production of expanded CD4
+CD25
+ T cells was
assayed by sandwich ELISA. Data shown are means6SD. *, P,0.05 compared with controls.
doi:10.1371/journal.pone.0007034.g009
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7034the proteins, computational structure predictions will provide
valuable information for the large fraction of sequences whose
structures will not be determined experimentally.
Recently, studies have indicated that the biological functions of the
peptide-major histocompatible complex (MHC) depend on the
structural property of the peptide [46,47]. Here, we focused on the
correlation of epitope structural properties with their functions in
e x p a n d i n gt h e r a p e u t i cT r e g s .Q u i n ne ta l .[ 9 ]c a r r i e do u te x p e r i m e n t s
on peptide epitope immunization and showed that GAD524–543
consisted of at least two I-A
g7-restricted determinants (p524 and p530,
GAD530–543), with apparently distinct properties. P524-specific T
cells dominate the protective response after immunization with
GAD524–543, while CD4
+ T cells arise spontaneously in young
NOD mice in response to a dominant determinant found within p530.
Consistent with this we have shown a difference in structural properties
between p524 and p530 using molecular modeling (Figure 6 and 7).
This difference may influences the conformation of MHC class II I-A
g7
in NOD mice when bound to the corresponding peptide epitopes, as
previously reported [48].
To address this issue, the patterns of p524, p530, p509 bound to
I-A
g7 were determined by molecular modeling using the structural
framework of GAD peptide p207 (GAD207–220) bound to I-A
g7
[49]. The structural properties and binding pattern to I-A
g7 of
another defined protective GAD peptide epitope, p286 (GAD286–
300) [41], used here as a positive control, were also analysed. We
found that the secondary structures of p524 and p286 were alpha-
helices and stable, while peptides p509 and p530 were coiled and
very flexible. The 3-D structure of I-A
g7 in complex with peptides
p509,p524,p530and p286 revealed two kindsofbindingmode;the
binding mode of I-A
g7 to p524 and p286 was similar, but markedly
different from its binding mode with p509 and p530 (Figure 8).
Overall, our data strongly suggest that protective peptide epitopes
p524 and p286,bindingto I-A
g7, could form a unique conformation
on the surface of APCs, allowing for the induction of Tregs.
To support this premise we analyzed another epitope p570,
which is very similar to p524 in sequence tendency, surface
electrostatic potential and interaction mode with I-A
g7. Similar
structural properties and binding patterns of p570 to I-A
g7,t o
those of p524 or p286 were revealed in this analysis. The fact that
p570 stimulation facilitated induction of IL-10/TGF-b-secreting
CD4
+CD25
+ T cells indicates that p570 is a protective epitope.
Therefore, while further comprehensive study is required, our
present data highlight that computer modeling-based T cell-
epitope study is a promising tool for function prediction of many
autoimmune-related epitopes. We are currently analyzing the
epitopes of another two critical autoimmune diabetes-related
autoantigens (i.e. insulin and IA-2) using molecular modeling.
To our knowledge, this is the first report of molecular modeling-
based analysis of T cell epitope function and prediction. Classical
approaches, such as use of 15-mer overlapping synthetic peptides,
are costly and time-consuming. With the help of molecular
modeling, it will become possible to carry out large-scale screening
of antigen/peptide targets, providing valuable structural informa-
tion as well as predicting potential epitopes and their functions.
Interestingly, to date, several of the GAD-specific clones isolated
have been found to be pathogenic and quite a few are non-
pathogenic [50,51]. Accumulating evidence indicates that many
GAD-specific responses may be protective and not diabetogenic.
As a result, it is reasonable that GAD should be used preferentially
as an immunogen to induce protective effects or to abrogate
aggressive autoimmunity. The present study proposes two
important regulatory epitopes (p524 and p570) in the region of
GAD500–585 for expanding functional Tregs. These findings may
be helpful for the design of autoimmune-related autoantigen
epitopes for immune intervention and achievement of therapeutic
epitope-specific Tregs.
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Figure 10. P570-expanded CD4
+CD25
+ T cells suppressed development of diabetes. (a) Diabetic splenocytes (1610
7) were co-transferred
with CD4
+CD25
+ T cells expanded by p570 to 4–8 wk old NOD.scid mice at the numbers indicated. Control recipients were injected with diabetic
splenocytes (1610
7) alone. In some cases, NOD.scid recipients receiving 6610
6 p570-expanded CD4
+CD25
+ T cells were injected with neutralizing
antibodies to IL-10/TGF-b according to the regimens described in Materials and Methods. Blood glucose levels were monitored for up to 8 wks.
Differences between diabetic spleens alone and diabetic spleens plus 3610
6 p570-expanded CD4
+CD25
+ T cells were significant (P=0.0039), as were
differences between diabetic spleens alone and diabetic spleens plus 6610
6 p570-expanded CD4
+CD25
+ T cells (P=0.0031). (b) P570-expanded
CD4
+CD25
+ T cells were transfused into 4–6 wk old NOD mice at the numbers indicated. Untreated littermates were used as controls. In some cases,
NOD recipients receiving 3610
6 p524-expanded CD4
+CD25
+ T cells were injected with neutralizing antibodies to IL-10/TGF-b according to the
regimens described in Materials and Methods. Development of diabetes was monitored over 25 wks. The difference between untreated controls and
mice transfused with 1610
6 p570-expanded CD4
+CD25
+ T cells was significant (P=0.0043), as was the difference between untreated and 3610
6
p570-expanded CD4
+CD25
+ T cells (P=0.0025). The number of mice in each group is indicated in parentheses.
doi:10.1371/journal.pone.0007034.g010
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